Synergistic effect of D-003 and aspirin on experimental thrombosis models

Abstract

D-003 is a mixture of higher primary aliphatic saturated acids purified from sugarcane wax, with antiplatelet and antithrombotic effects experimentally demonstrated. Octacosanoic acid is the main component of D-003, followed by triacontanoic, dotriacontanoic, and tetracontanoic acids, while other acids are minor components. This work investigates the effects of combination therapy D-003+aspirin (ASA) on arachidonic acid (AA)-induced sudden death in mice and bleeding time in rats. In addition, the effects of D-003 on serum levels of two metabolites of AA: thromboxane A₂ and prostacyclin, assessed through the measurement of their stable metabolites: thromboxane B₂ (TxB₂) and 6 keto PgF1α by radioimmunoassay kits, were also investigated. Combination therapy of D-003 (50 mg/kg) and ASA (3 mg/kg) significantly increased bleeding time in rats in a synergistic manner compared with D-003 or ASA alone. Moreover, the combined treatment of D-003 (200 mg/kg) and ASA (5 mg/kg) in mice protected against AA-induced sudden death (83% survivors) in a synergistic manner which was compared with each treatment alone (33% survivors). These results indicate that antiplatelet effects of D-003 are not mediated by a cyclooxygenase inhibition. D-003 and ASA monotherapies reduced serum TxB₂ levels, whereas D-003, but not ASA, significantly increased 6 keto PgF1α levels.